Storz, L.; Walther, P.; Chemnitzer, O.; Lyros, O.; Niebisch, S.; Mehdorn, M.; Jansen-Winkeln, B.; Moulla, Y.; Büch, T.; Gockel, I.;
et al. Nrf2/Keap1-Pathway Activation and Reduced Susceptibility to Chemotherapy Treatment by Acidification in Esophageal Adenocarcinoma Cells. Cancers 2021, 13, 2806.
https://doi.org/10.3390/cancers13112806
AMA Style
Storz L, Walther P, Chemnitzer O, Lyros O, Niebisch S, Mehdorn M, Jansen-Winkeln B, Moulla Y, Büch T, Gockel I,
et al. Nrf2/Keap1-Pathway Activation and Reduced Susceptibility to Chemotherapy Treatment by Acidification in Esophageal Adenocarcinoma Cells. Cancers. 2021; 13(11):2806.
https://doi.org/10.3390/cancers13112806
Chicago/Turabian Style
Storz, Lucie, Philipp Walther, Olga Chemnitzer, Orestis Lyros, Stefan Niebisch, Matthias Mehdorn, Boris Jansen-Winkeln, Yusef Moulla, Thomas Büch, Ines Gockel,
and et al. 2021. "Nrf2/Keap1-Pathway Activation and Reduced Susceptibility to Chemotherapy Treatment by Acidification in Esophageal Adenocarcinoma Cells" Cancers 13, no. 11: 2806.
https://doi.org/10.3390/cancers13112806
APA Style
Storz, L., Walther, P., Chemnitzer, O., Lyros, O., Niebisch, S., Mehdorn, M., Jansen-Winkeln, B., Moulla, Y., Büch, T., Gockel, I., & Thieme, R.
(2021). Nrf2/Keap1-Pathway Activation and Reduced Susceptibility to Chemotherapy Treatment by Acidification in Esophageal Adenocarcinoma Cells. Cancers, 13(11), 2806.
https://doi.org/10.3390/cancers13112806
